Quantum Genomics to Participate in Biotech Showcase 2020
December 16, 2019 12:00 ET
|
Quantum Genomics
PARIS and NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug...
Quantum Genomics and Biolab Sanus Pharmaceutical Enter into Exclusive Licensing and Collaboration Agreement for Firibastat in Latin America
December 09, 2019 12:00 ET
|
Quantum Genomics
PARIS and NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly...
Quantum Genomics Enters Into Exclusive Negotiations for its First Partnership
October 07, 2019 01:30 ET
|
Quantum Genomics
PARIS and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug...
Quantum Genomics Reports First Half 2019 Financial Results and Provides Corporate Update
October 03, 2019 12:00 ET
|
Quantum Genomics
Arterial hypertension: preparing for the pivotal Phase III study of firibastat in patients with resistant arterial hypertension Heart failure: the first patients were enrolled in June in...
Quantum Genomics Launches Study of Firibastat in Patients with Renal Failure
September 11, 2019 13:34 ET
|
Quantum Genomics
PARIS and NEW YORK, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that a...
Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension
September 02, 2019 12:00 ET
|
Quantum Genomics
PARIS and NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Quantum Genomics Selected to Enter the European Rising Tech Label
July 03, 2019 12:00 ET
|
Quantum Genomics
PARIS and NEW YORK, July 03, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...
Quantum Genomics Announces Result of Annual General Meeting
June 27, 2019 12:00 ET
|
Quantum Genomics
PARIS and NEW YORK, June 27, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical...
A key milestone reached by Quantum Genomics in the development of firibastat
June 12, 2019 12:00 ET
|
Quantum Genomics
A novel 500 mg controlled-release tablet of firibastat offering an optimal pharmacokinetic profile for once-a-day dosing has been identified PARIS and NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) --...
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat in Heart Failure Patients
June 06, 2019 12:00 ET
|
Quantum Genomics
PARIS and NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that...